Advanced knowledge in the field of stem cell biology and their ability to provide a cue for counteracting several diseases are
leading numerous researchers to focus their attention on \u201cregenerative medicine\u201d as possible solutions for cardiovascular diseases
(CVDs). However, the lack of consistent evidence in this arena has hampered the clinical application. The same condition affects
the research on endothelial progenitor cells (EPCs), creating more confusion than comprehension. In this review, this aspect is
discussed with particular emphasis. In particular, we describe biology and physiology of EPCs, outline their clinical relevance as
both new predictive, diagnostic, and prognostic CVD biomarkers and therapeutic agents, discuss advantages, disadvantages, and
conflicting data about their use as possible solutions for vascular impairment and clinical applications, and finally underline a very
crucial aspect of EPCs \u201ccharacterization and definition,\u201d which seems to be the real cause of large heterogeneity existing in literature
data on this topic